Reductions in patients' co-payments for Polish drugs is one of the mechanisms included in the amendment to the Drug Reimbursement Law, which is intended to build Poland's drug security and encourage an increase in pharmaceutical production in our country. Currently, the share of domestic drugs accounts for 35% of the value of the reimbursed drug market, while by sales volume it is 48%.
Building system resilience
Experience from the Covid-19 pandemic has proven that the more drugs produced domestically, the lower the risk of shortages during emergencies. After all, one of the reasons for pharmaceutical shortages in the EU is dependence on supplies from outside Europe. Meanwhile, the transport of pharmaceutic...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
